One of the most used nonsteroidal-antiinflammatory drugs (NSAID), Ibuprofen (Ib), causes frequent gastrointestinal side effects when treating chronic conditions such as arthritis and osteoarthritis. The development of new delivery systems will avoid the use of the oral formulations of this drug and the side effects associated with its long-term use. Lately, supramolecular gels, especially organogels, have played a major role in the design of new controlled drug release systems. The tripeptide organogelator Z-L-Phe-L-Phe-L-Ala-NH2 was synthesized in order to test its gelling properties, storage capacity and the controlled release of Ib. The saturated fatty acid esters and vegetable oils were selected for the liquid phase of the organogels. The selected gelling solvents are biocompatible and have the property of enhanced permeation through the skin, which is desirable for the development of transdermal controlled delivery systems. Ib was incorporated into various organogels and was monitored for release into accepting media - phosphate buffers of different pH values. The concentration of released Ib was calculated using the Beer-Lambert law equation, using absorbance previously measured in a cuvette or with UV-Vis optical probe. The results of the study show that organogels with Z-L-Phe-L-Phe-L-Ala-NH2 and saturated fatty acid esters or vegetable oils are good storage systems for lipophilic Ib. The release of Ib depends significantly on the pH value of the receiving medium, but also on the solvent used in the preparation of the organogels. The release of Ib is better in basic medium (pH 7.4) than in acidic (pH 6.0). Ibuprofen release was followed by UV-Vis spectroscopic methods showing the same results under the same conditions.